Below, find a brief listing of our Biological Mimetics Management team.
"Bringing Creativity to the Biomedical Industry"
Dr. Gregory J. Tobin, President, CEO, Director
President and CEO. Dr. Tobin has led research and technical programs at BMI since 1999. A vaccinologist and molecular biologist, Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; and coordination of multi-site studies. Dr. Tobin fosters a highly interactive research and development group to apply the Company’s two proprietary technologies (Novel Inactivated Vaccines and Immune Refocusing Technology) to the design of improved vaccines.
Current research projects employ the technology used in UltraIPV to the derivation of vaccines against two antibiotic-resistant bacteria, Acinetobacter baumannii and MRSA. In addition, Dr. Tobin’s work includes the use of Immune Refocusing in the design of the first vaccine against human rhinovirus (HRV) and of a broadly protective influenza vaccine. Dr. Tobin has been the Principal Investigator or technical lead on twelve NIH grants, seven DOD research contracts, and several grants funded by other agencies or companies.
Dr. David S. Silberstein, Director, Scientific Advisor
Director and Scientific Advisor. Dr. Silberstein received his PhD in Microbiology at Columbia University and Postdoctoral training at Harvard Med School/Brigham & Women’s Hospital. He continued for seven years with a faculty appointment at Harvard, leading an NIH-funded research team studying the biochemistry of lung inflammation.
This was followed by 20 years at AstraZeneca Pharmaceuticals where he had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion. Since 2013, he has worked as an advisor and company officer with a number of early stage biotech companies and as a consultant to investment firms.
Mr. A Gregory Kelly, MS, MBA, CPA, Chairman of the Board
Chair, Board of Directors. Greg Kelly, M.S., M.B.A., has been an active member of Maryland’s emerging business community for over 35 years. He has invested in a number of early-stage companies, and he has founded, been a Board Member of, or been a strategic advisor and financial consultant to numerous other companies.
For 20 years, Greg served in the Health Care & Life Sciences practice of KPMG in Baltimore, where he managed or provided public and private offerings assistance, financial structuring advice , transactions services, small and large company performance improvement initiatives, and attestation services.
Greg is currently a founder, the Co-President, the Chief Science Officer and the Chief Financial Officer of Blue Ocean Biosystems, Inc. in Easton, Maryland, and the Managing Director of Acadine Ventures, LLC.
Dr. Steve Dollery, Staff Scientist
Microbiologist/Immunologist/Vaccinologist: Stephen J. Dollery, Ph.D. is a Staff Scientist at BMI where he leads research in multiple fields. To advance his goal of improving global health, Dr. Dollery applies his expertise in molecular structure, molecular biology and immunology to lead several vaccine and diagnostic projects and to direct funding and development efforts. Dr. Dollery has been the Principal Investigator on the Company’s NIH-NIAID SBIR grant entitled, “Whole-cell Vaccine Development for MRSA.” Dr. Dollery is a renowned expert in the mechanisms of viral entry has been the first author on six peer-reviewed scientific publications in the past four years alone. Dr Dollery is deeply involved with developing the companies “ultra” and immune-refocused vaccine platforms (A. baumannii, polio, influenza) and diagnostics (HPV, malaria, Leishmania).
Dr. Dollery received his doctorate in Microbiology and Immunology while studying the virus entry pathways of human herpesviruses. He continued training, and was then employed by, the NIH as a postdoctoral researcher and then a fellow in the Molecular Structure Section of the Laboratory of Viral Diseases. https://orcid.org/0000-0002-1712-3811
Taralyn Wiggins, Program Manager
Taralyn Wiggins, M.S., joined BMI in 2011 as a fresh graduate from James Madison University. Initially full time in the laboratory Taralyn displayed a keen interest in protein production and purification process optimization. After Taralyn obtained her Masters in Biotechnology and Management in 2016 she began expanding her responsibilities into grant writing and project management. By 2018 Taralyn was appointed Program Manager overseeing all of BMI’s current NIH and DoD grants as well as a contributor and reviewer of BMI grant submissions. Her organizational and strong communication skills are invaluable to hit the milestone objectives, thoroughly document and report results, and foster relationships with collaborators.
For further information, please use our Contact Us Form